Adagio CMO Lynn Connolly resigns; Hershberger takes over clinical development

Invivyd, Inc.

CMO Lynn Connolly resigns effective March 25, 2022, to tend to family obligations.
Connolly remains through ADG20 Phase 2/3 data analysis and transition of duties.
Chief Development Officer Ellie Hershberger permanently assumes responsibility for clinical development programs.
Company expects to enter into a consulting agreement with Dr. Connolly.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Lynn Connolly

Chief Medical Officer

IVVD · Invivyd, Inc.

Effective: 2022-03-25
Filed: March 1, 2022, 6:59 PM ET

Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc. (the “Company”), has resigned her position, effective as of March 25, 2022, to tend to family obligations.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lynn Connolly resigned as Chief Medical Officer at Invivyd, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc. (the “Company”), has resigned her position, effective as of March 25, 2022, to tend to family obligations.

View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-061608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.